Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from May 1, 2010, to October 31, 2010. The document serves as a Block Listing Six Monthly Return, detailing the status of unallotted securities under various employee share option schemes. It does not contain general business operations or financial performance data.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to equity compensation scheme data.
Material Changes in Share Option Schemes
The filing reports changes in the balance of unallotted securities for eight distinct share option schemes. No new securities were added to any scheme during the period. Issuances occurred in three specific plans:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: 1,103,185 securities issued; ending balance 2,092,426.
- GlaxoSmithKline Share Option Plan - ADS: 1,176,286 securities issued; ending balance 4,007,856.
- GlaxoSmithKline Savings Related Share Option Scheme: 196,371 securities issued; ending balance 4,263,507.
Five other schemes (including Glaxo Wellcome UK/International and SmithKline Beecham plans) reported zero issuances, with balances remaining unchanged from the previous return.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items.
Key Facts for Investor Verification
- Total securities issued across all reported schemes during the period: 2,475,842.
- Total unallotted securities remaining at period end across all schemes: 29,060,071.
- No increases were applied for or granted to any block scheme during the six-month period.
- Contact for scheme inquiries: Victoria Whyte.